MRI T1 Relaxation Time in Rectal Cancer

MRI T1 Relaxation Times in Evaluating Neoadjuvant Treatment of Rectal Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05876026

Enrollment

Registered

2023-05-25

Start date

2023-05-08

Completion date

2025-12-31

Last updated

2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced Rectal Carcinoma, Rectal Cancer

Brief summary

The goal of this observational study is to learn about the T1 relaxation time and T1 relaxation time properties of the disease in people with locally advanced rectal cancer. The main question it aims to answer is: Does MRI T1 relaxation time have a high diagnostic performance in recognizing fibrosis as a complete response to neoadjuvant treatment of rectal cancer? Participants will receive standard neoadjuvant treatment and be part of the standard examination programme regarding rectal cancer.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* rectal cancer, age \>18 years

Exclusion criteria

* contraindications for MRI (pacemaker, claustrophobia, implanted medical injectors and nerve stimulators), * previous radiochemotherapy or another disease which investigator judges inappropriate for the persons continued participation.

Design outcomes

Primary

Measure	Time frame	Description
Difference in T1 relaxation time (ms) in the rectal cancer tumor measured in IntelliSpace-software before and after neoadjuvant radiochemotherapy.	6 to 8 weeks.	An MRI T1 relaxation time-map is performed on each participant. The data is transferred to IntelliSpace-software for measurement and mapping. It is measured in miliseconds (ms) before and after neoadjuvant treatment.

Countries

Denmark

Outcome results